Case Report

Successful Treatment of Refractory Childhood Pemphigus with Rituximab


  • Ankur Sarin
  • Jushya Bhatia
  • Kailash Bhatia

J Turk Acad Dermatol 2017;11(3):0-0


Rituximab is an anti-CD 20 monoclonal antibody used to treat Chronic Lymphocytic Leukemia and Rheumatoid Arthritis. In dermatology, rituximab has gained popularity for the treatment of refractory pemphigus vulgaris. However, there are only a few case reports regarding the treatment of refractory childhood pemphigus with rituximab. We are reporting this case as childhood pemphigus is rare, and the safety of rituximab in children is unknown due to the paucity of studies.

Keywords: Rituximab, childhood pemphigus, refractory pemphigus vulgaris